What is the difference between Cerebrolysin and Cortexin?

Cerebrolysin: Cerebrolysin is a brain-derived peptide mixture produced by controlled enzymatic breakdown of porcine brain proteins. Unlike synthetic peptides, it is a complex of ~25% low-molecular-weight neuropeptides and ~75% free amino acids, with the bioactive peptide fraction mimicking the endogenous neurotrophic factors BDNF, NGF, GDNF, and CNTF in their mechanisms. It has a 30+ year clinical history in Eastern Europe and Asia for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia — with a substantial human trial database. Cortexin: Polypeptide nootropic extracted from the cortex of cattle or pigs, containing a mixture of low-molecular-weight neuropeptides (≤10 kDa). Registered pharmaceutical in Russia and widely used in Eastern European clinical medicine for stroke recovery, traumatic brain injury, cognitive decline, epilepsy, and cerebrovascular disease. Decades of Russian clinical literature support neuroprotective and neurorestorative effects. Both are in the Nootropic & Cognitive category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take Cerebrolysin and Cortexin together?

There is no specific, well-documented interaction rule for combining Cerebrolysin and Cortexin in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Cerebrolysin or Cortexin?

Cerebrolysin is currently research-stage and Cortexin is research-stage. "Better researched" depends on your research goal — review each profile's cited sources.

Nootropic & Cognitive · Comparison

Cerebrolysin vs Cortexin

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Cerebrolysin

Research-stage

Cerebrolysin is a brain-derived peptide mixture produced by controlled enzymatic breakdown of porcine brain proteins. Unlike synthetic peptides, it is a complex of ~25% low-molecular-weight neuropeptides and ~75% free amino acids, with the bioactive peptide fraction mimicking the endogenous neurotrophic factors BDNF, NGF, GDNF, and CNTF in their mechanisms. It has a 30+ year clinical history in Eastern Europe and Asia for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia — with a substantial human trial database.

Full profile

Cortexin

Research-stage

Polypeptide nootropic extracted from the cortex of cattle or pigs, containing a mixture of low-molecular-weight neuropeptides (≤10 kDa). Registered pharmaceutical in Russia and widely used in Eastern European clinical medicine for stroke recovery, traumatic brain injury, cognitive decline, epilepsy, and cerebrovascular disease. Decades of Russian clinical literature support neuroprotective and neurorestorative effects.

Full profile

	Cerebrolysin	Cortexin
Category	Nootropic & Cognitive	Nootropic & Cognitive
Also known as	FPF 1070, EBEWE Cerebrolysin, Brain-derived peptide mixture	cortexin polypeptide, cortexin-10, neuropeptide bioregulator, cortexin-5
Evidence	Research-stage	Research-stage
Dosing range	5mL–30mL mL, Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access	5mg–20mg mg, daily IM injection for 10-day courses
Administration	Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common)	Intramuscular injection
Key side effects	Injection site pain (IM route), Hyperthermia / fever (rare, higher doses), Agitation or anxiety (uncommon), Nausea	Injection site pain, Rare allergic reaction, Headache (transient), Mild dizziness
Cited sources	3 references	2 references

Key differences

Administration: Cerebrolysin — Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min), Intramuscular injection (research use — lower bioavailability), Subcutaneous injection (less common); Cortexin — Intramuscular injection.
Dosing units differ: Cerebrolysin is dosed in mL, Cortexin in mg — they operate at different scales.
Frequency: Cerebrolysin is typically Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access; Cortexin is daily IM injection for 10-day courses.
Research depth: this profile cites 3 sources for Cerebrolysin vs 2 for Cortexin.

How each works

Cerebrolysin

Cerebrolysin's neuroprotective effects have been demonstrated in over 100 clinical trials, though most are from Eastern European and Asian centers with varying methodological quality. The CACTUS trial (N=256, multicenter) showed significant improvement in cognitive outcomes after ischemic stroke vs placebo. The ARTIST trials evaluated Cerebrolysin for Alzheimer's disease with mixed results. Meta-analyses of stroke and dementia trials generally support modest-to-moderate benefit. Mechanistically, the peptide fraction upregulates BDNF/NGF signaling, reduces excitotoxicity, inhibits caspase-3, and promotes synaptogenesis in animal and in vitro models.

Cortexin

Cortexin's multi-component neuropeptide mixture modulates neurotransmitter systems, improves cerebral blood flow, enhances neuroplasticity (BDNF upregulation), and exhibits antioxidant and anti-apoptotic activity in neuronal tissue. Russian stroke rehabilitation trials show improved neurological deficit scores and functional recovery with 10-day cortexin courses compared to standard care alone. The mechanism involves multiple parallel neuropeptide signaling pathways.

Read the full Cerebrolysin profile Read the full Cortexin profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.